SAN DIEGO, Oct. 23 /PRNewswire/ -- Naviscan, Inc., the leader in Molecular Breast Imaging (MBI), today announced that Paul J. Mirabella, President and Chief Executive Officer, will be presenting a corporate update at the 4th Annual BIOCOM Investor Conference on October 27, 2009 at 1:00 p.m. being held at Hyatt Regency in La Jolla, California.
The presentation will include a summary of a 388-patient, NIH-sponsored clinical trial comparing their high-resolution breast PET system, Positron Emission Mammography (PEM) scanner, to breast Magnetic Resonance (MR).
“These exciting results, especially during Breast Cancer Awareness Month, will be welcomed news by patients and physicians as a new and effective tool in management of the breast cancer patient,” said Mirabella.
About Naviscan, Inc.
Naviscan Inc., founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging, guide radiological and surgical procedures and advance new clinical therapies. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. as well as utilized in clinical research studies, funded in part by the National Institutes of Health. The Company is headquartered in San Diego, California and is the first company to obtain FDA clearance of a high-resolution PET scanner designed to image small body parts. For more information, call 1.858.587.3641 or visit www.naviscan.com.
SOURCE Naviscan Inc.
CONTACT: Guillaume Bailliard, VP, Marketing of Naviscan PET Systems, Inc.,
+1-858-332-0941
Web site: http://www.naviscan.com/
